Company News
FEBRUARY 2024 | Outcomes Meet or Exceed Benchmarks
Vigor is proud to announce that its 2023 full-year US clinical outcomes meet or exceed its evidence-based benchmarks for engagement, retention, safety, and reductions in healthcare utilization. Vigor achieves high patient satisfaction and is on track to deliver 10X return on investment for payers.
JANUARY 2023 | Commercial Launch in USA
Vigor is excited to announce the commercial launch of its home-based chronic respiratory disease management programs in the USA. Vigor engages B2B with payer and value-based provider organizations to provide coordinated and integrated care through innovative value-based contracting approaches.
OCTOBER 2022 | Commercial Launch in India
Vigor is excited to announce the commercial launch of its home-based chronic respiratory disease management program in India after nine months of prototyping and training. Vigor’s initial patient cohort experience significant improvements in function and outcomes, and promote the program to their family and friends.
JUNE 2022 | Featured Startup at McKinsey Early Stage Investor Conference
Vigor is grateful and honored to be invited to dialogue with business executives, industry experts, and investors in vital technology sectors and to share the story of how Vigor will use data+science to improve outcomes for the world’s third leading cause of death.
FEBRUARY 2022 | Second US Patent Granted
Vigor is proud to receive a second US Patent for its system for remotely delivering comprehensive digital pulmonary management and rehabilitation programs to individuals and groups. The new patent includes claims covering medication management, multidisciplinary therapeutics, multimedia education, remote monitoring, and secure multimodal telehealth services.
DECEMBER 2021 | Hello Tomorrow Deep Tech Pioneer
Vigor is excited to be selected as a Deep Tech Pioneer by Hello Tomorrow, headquartered in Paris, France, and to join its global community of the most promising startups in deep tech.
DECEMBER 2021 | European Patent Granted
Vigor is excited to receive a European Patent on its method and technology for measuring & monitoring lung function and remotely managing respiratory conditions, in addition to its existing US Patent. The new patent includes more than twenty claims covering digital treatment or rehabilitation programs and remote clinical trials or research studies.
APRIL 2021 | Equity Funding Round
Vigor is excited to close an equity round by a professional VC syndicate from Austin, Boston, Hong Kong, and Singapore. Springtide Investments led this oversubscribed funding round.
DECEMBER 2020 | Featured Startup at McKinsey Early Stage Investor Conference
Vigor is grateful to be selected for presentation at this forum of global executives, experts, and investors in key technology sectors. Vigor raised awareness of global unmet needs in chronic respiratory diseases and our solutions for addressing those needs sustainably.
JULY 2020 | MedTech Innovator Asia Pacific Accelerator Company
Vigor is honored to be selected from a pool of 200+ applicants by MedTech Innovator as one of twenty “best of the best” medtech startups in APAC transforming healthcare through innovation.
SEPTEMBER 2019 | Verge HealthTech Fund Portfolio Company
Vigor is proud to be part of the Verge HealthTech Fund family, to expand access to sustainable and equitable health care around the world through new delivery models enabled by impactful technology.
JUNE 2019 | Johnson & Johnson Innovation Partner, JLABS@Shanghai & JLABS@TMC (Texas Medical Center)
Vigor is honored to be selected by Johnson & Johnson Innovation as a partner of JLABS@Shanghai, the world’s largest JLABS and the first in the Asia Pacific region, and as a partner and resident of JLABS@TMC.
JANUARY 2017 | Breakthrough Companies Featured at the CED Life Science Conference
Vigor is honored to be selected as one of 24 companies to present live on stage at the Council for Entrepreneurial Development (CED) Life Science Conference 2017, in front of 1,000 attendees including the most active, influential investors and life sciences leaders from across the United States.